ZYNTEGLO is made specifically for each patient, using the patient's own blood stem cells and adds functional copies of the beta-globin gene to your cells. This ...

Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the treatment for beta thalassemia. ... Mechanism of action. edit. Beta ...

22 авг. 2022 г. · Betibeglogene autotemcel is an autologous gene therapy that adds functional copies of the β-globin gene (β A-T87Q -globin) to hematopoietic stem cells in order ...

29 мая 2019 г. · Mechanism of action. Zynteglo adds functional copies of a modified β-globin gene into the patients' HSCs through transduction of autologous ...

The patients go through autologous hematopoietic stem cell mobilization and harvesting. The harvested cells are transduced ex vivo with self-inactivating ...

28 июн. 2019 г. · The drug restores the β-globin protein in patients by adding normal copies of the modified β-globin gene into the HSC of the patients through ...

For intravenous use only. • Patients are required to undergo hematopoietic stem cell (HSC) mobilization followed by apheresis to obtain CD34+ cells for ZYNTEGLO.

Mechanism of action. Zynteglo adds functional copies of a modified β-globin ... effects of Zynteglo. During the long-term follow-up, your doctor will ...

25 авг. 2022 г. · Mechanism of action: Zynteglo adds functional copies of a modified β-globin gene into patients' hematopoietic stem cells (HSCs) through ...